Page 258 - Binder2

1. Build Industrial-Grade Expression Platforms

The science is sound, but the platform must scale.
We need plant-based expression systems that deliver
repeatable, GMP-compliant, pharma-grade outputs—
not just promising yields in research labs.

That means:

• Codifying best practices for plant transformation
and protein folding
• Optimizing growth conditions for consistent
biomass and therapeutic load
• Developing standard operating procedures for
harvest, processing, and formulation
• Proving that lettuce, duckweed, and rice aren’t just
model organisms—they’re manufacturing
workhorses

If edible biologics are to be taken seriously by investors,
regulators, and healthcare systems, they must match the
reliability, quality control, and scalability of traditional
bioreactors.

We don’t need perfect plants.
We need platforms that perform—batch after batch, dose
after dose.

2. Define New Regulatory Precedents

Edible biologics don’t fit neatly into existing drug
categories.
They blur the lines between food, pharma, and device—and
that ambiguity can stall progress.

256